Latest Headlines

Latest Headlines

AMRI's expansion binge pays off for CMO

New York-based CMO AMRI has seen its contract manufacturing grow big time after picking up a number of competitors. CEO William Marth says after its latest deal for a Spanish specialty drugmaker, that growth should carry through the year.

AMRI swings to a profit as it slogs through a turnaround

AMRI, rebuilding its business after a string of slow quarters, posted a profit for the first time in 12 months as it looks to hit its stride as a growing contract drug developer.

AMRI bets $174M on manufacturing with latest buyout

Contract drugmaker AMRI paid $174 million for a Spanish manufacturing operation, part of the company's long-term plan to dial up its focus on production.

AMRI picks up Spanish drugmaker in $174M deal

Albany, NY-based contract manufacturer AMRI has continued its buying spree for more and more diverse manufacturing capacity, and the deals are getting larger. Its latest is a $174 million deal for a drugmaker in Spain that makes specialty APIs and sterile injected drugs.

AMRI shells out $174M for a Spanish drugmaker

Contract drug developer AMRI bought Spain's Gadea Pharmaceutical for $174 million, picking up a company focused on the manufacture of active ingredients and finished treatments.

AMRI recruits PerkinElmer to build out a new R&D hub

AMRI, in the process of consolidating its drug discovery services, is teaming up with life sciences giant PerkinElmer to accelerate a new biomedical hub in Buffalo, NY.

AMRI partners up in drug discovery amid a corporate turnaround

Contract drugmaker AMRI is shifting some of its focus to early-stage R&D, partnering up with a neighboring biotech to expand its capabilities in drug discovery.

Manufacturing moves pay off for AMRI

Contract manufacturer AMRI has been reworking its manufacturing assets, picking up valuable pieces here and there and then sacrificing a less important one as it moves toward contract manufacturing and away from a reliance on royalties. Its most recent earnings suggest the strategy is paying off on the top line at least.

AMRI swings to another loss despite big sales gains

Contract drug developer AMRI, on the mend after a series of setbacks, posted a 38% sales boost to start the year, but the costs of an ongoing transition dragged it into the red for yet another quarter.

AMRI shutters another plant with an eye on its bottom line

Contract drug developer AMRI is closing down a U.K. manufacturing operation as part of its across-the-board change in strategy, an effort to get back to growth after a rough string of quarters.